Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Nasal_Spray
Hikma has described Ryaltris as "very interesting" • Source: Shutterstock

Hikma Pharmaceuticals’s commercialization agreement with Glenmark Pharmaceuticals in the US covering rights for the Indian firm’s Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray is set to bear fruit two years after the deal was signed, following US Food and Drug Administration approval for the seasonal allergic rhinitis treatment.

Glenmark has lauded a “major milestone,” noting that its approval for the 505(b)(2) hybrid new drug application product “clearly supports...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.